Medicamen Biotec

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE646B01010
NSEID: MEDICAMEQ
BSEID: 531146
View on NSE | View on BSE

INR

328.05

-18.25 (-5.27%)

BSENSE

Sep 18, 03:30 PM

BSE+NSE Vol: 31.32 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Albert David

Trident Lifeline

Valiant Laborato

Medicamen Biotec

Jenburkt Pharma

Haleos Labs Limi

Influx Health.

Infinium Pharma

Transchem

Aptus Pharma

Astonea Labs

Why is Medicamen Biotech Ltd ?

Poor long term growth as Operating profit has grown by an annual rate -7.65% of over the last 5 years

Flat results in Jun 26

PBDIT(Q) Lowest at Rs 4.33 cr.
EPS(Q) Lowest at Rs 1.56

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Medicamen Biotec for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Medicamen Biotec

-1.6%

-0.03

48.50%

Sensex

-10.5%

-0.78

13.50%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.50%

EBIT Growth (5y)

-7.65%

EBIT to Interest (avg)

4.58

Debt to EBITDA (avg)

1.55

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

0.66

Tax Ratio

19.24%

Dividend Payout Ratio

14.07%

Pledged Shares

Institutional Holding

0.53%

ROCE (avg)

6.97%

ROE (avg)

6.16%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.63

EV to EBIT

38.38

EV to EBITDA

24.05

EV to Capital Employed

1.59

EV to Sales

2.29

PEG Ratio

2.93

Dividend Yield

0.61%

ROCE (Latest)

4.24%

ROE (Latest)

3.94%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET SALES(9M)

At Rs 155.46 cr has Grown at 31.98%

PAT(Latest six months)

At Rs 5.98 cr has Grown at 30.85%

-2What is not working for the Company

PBDIT(Q)

Lowest at Rs 4.33 cr.

EPS(Q)

Lowest at Rs 1.56

Loading Valuation Snapshot...

Here's what is working for Medicamen Biotec

Net Sales - Latest six months

At Rs 108.55 cr has Grown at 49.42%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months

At Rs 5.98 cr has Grown at 30.85%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Medicamen Biotec

Operating Profit (PBDIT) - Quarterly

Lowest at Rs 4.33 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Earnings per Share (EPS) - Quarterly

Lowest at Rs 1.56

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)